Core Viewpoint - The report from CITIC Securities indicates that medical AI will accelerate the restructuring of the trillion-dollar pharmaceutical market, with a fundamental change in the logic of AI healthcare expected by 2026 due to clearer and stronger payment sources this year [1] Summary by Categories AI Healthcare Commercialization - 2026 is anticipated to be a year with stronger certainty in the commercialization of AI healthcare, opening up more opportunities for business in this sector [1] Key Focus Areas - The report suggests focusing on five main areas: AI pharmaceuticals, grassroots AI healthcare applications, medical data circulation and trading, AI pathology diagnosis, AI medical models, and C-end expansion channels [1]

九强生物（300406.SZ）12月24日在投资者互动平台表示，指南的发布，从政策层面认可AI在病理诊断 中的应用价值，为病理数字化和新技术应用提供了制度基础，有阶段性积极意义。病理AI相关项目是 公司重点研发项目，当前，在研产品尚处于临床验证阶段，后续相关进展请以公司公告为准。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：国家医保局12月19日发布的病理检查诊断价格立项精 细化文件对公司的AI病理诊断是利好么？目前子公司迈新生物的AI病理诊断涵盖了多少省市和医院？ 公司的AI病理诊断准确率有多高？ ...